SOURCE: Inovio Biomedical Corporation

May 15, 2007 12:41 ET

Inovio to Present at 2007 San Diego Growth Conference

SAN DIEGO, CA -- (MARKET WIRE) -- May 15, 2007 -- Inovio Biomedical Corporation (AMEX: INO), focused on the development of genetic vaccines for cancers and infectious diseases and a novel therapy to replace surgery for treating cancers, announced today that Michael Fons, Ph.D., Executive Director, Corporate Development, will present a corporate overview at the California Stock Report's San Diego Growth Conference at 9:30 a.m. PT on Saturday, May 19, 2007 at the Hilton-La Jolla Torrey Pines hotel in La Jolla, California.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA-based immunotherapies using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around a tumor. Inovio is moving its lead product, the MedPulser®, through pre-marketing studies for head & neck and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for head and neck cancer, and a Phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA-based immunotherapies in Phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to increase both cellular uptake of a useful biopharmaceutical and, in the case of gene-based treatments, levels of gene expression. Inovio has the most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

Contact Information

  • CONTACT:
    Investor Relations
    Bernie Hertel
    Phone: (858) 410-3101

    Media Relations
    Jeff Richardson
    Phone: 805-491-8313